Welcome to our dedicated page for eXoZymes SEC filings (Ticker: EXOZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a company that turns waste biomass into life-saving APIs sounds thrilling—until you face the 250-page disclosures that outline every enzyme patent and regulatory hurdle. eXoZymes SEC filings explained simply is exactly what busy analysts need. Stock Titan distills the biotech jargon so you can focus on how AI-engineered exozymes reshape chemical manufacturing without trawling through dense PDFs.
Want the numbers fast? Our platform pairs AI-powered summaries with real-time EDGAR feeds, serving eXoZymes quarterly earnings report 10-Q filing highlights, cash-burn trends and segment revenue in minutes. Receive instant alerts for eXoZymes Form 4 insider transactions real-time and dig deeper into eXoZymes executive stock transactions Form 4. From an eXoZymes annual report 10-K simplified to an eXoZymes proxy statement executive compensation, you’ll see how R&D milestones, dilution risk and pay packages intersect. Even sudden catalyst news? Check the eXoZymes 8-K material events explained feed before the market reacts.
Here’s how professionals use the page:
- Monitor eXoZymes insider trading Form 4 transactions ahead of clinical data releases.
- Compare enzyme-platform economics quarter-over-quarter with our eXoZymes earnings report filing analysis.
- Save hours by understanding eXoZymes SEC documents with AI that flags patent updates, environmental disclosures and funding needs.
eXoZymes Inc. filed an 8-K announcing an updated Investor Presentation as of November 13, 2025. The update, tied to its NCTx business, is furnished under Item 8.01 (Other Events) and provided as Exhibit 99.1.
The company’s common stock trades on the Nasdaq Capital Market under the symbol EXOZ. The report lists the company’s principal office at 750 Royal Oaks Drive, Suite 106, Monrovia, CA 91016.
eXoZymes Inc. (EXOZ) filed its Q3 2025 10-Q, reporting continued operating losses and a going concern warning. The company posted a net loss of $2,286,991 for the quarter and $6,503,698 for the nine-month period. Basic and diluted EPS were $(0.27) for the quarter and $(0.78) year-to-date.
Cash and cash equivalents were $5,098,687 as of September 30, 2025, down from $9,719,310 at year-end, reflecting operating cash outflows of $4,528,240 for the nine months. Operating costs rose to $7,020,981 year-to-date, driven by higher general and administrative expenses of $4,426,216 and research and development costs, net of grants, of $2,594,765. Grants offset R&D by $1,120,907 year-to-date, including $256,474 in Q3.
The company recorded a discrete income tax receivable of $105,826 in Q3. Management states there is substantial doubt about the company’s ability to continue as a going concern given its pre-revenue status and anticipated funding shortfalls. Shares outstanding were 8,387,250 as of November 13, 2025.
FAQ
What is the current stock price of eXoZymes (EXOZ)?
What is the market cap of eXoZymes (EXOZ)?
